As it awaits piv­otal re­view of lead drug, Fi­bro­Gen bol­sters its ear­ly pipeline with li­cens­ing deal for galectin pro­gram

Fi­bro­Gen’s long-await­ed re­view for ane­mia med rox­adu­s­tat is just weeks away, and there’s good rea­son to be­lieve the out­come won’t swing in its fa­vor af­ter a da­ta ma­nip­u­la­tion scan­dal and tepid an­a­lyst con­sen­sus on the drug’s chances. With its fu­ture murky, Fi­bro­Gen is now open­ing the pock­et­book to re­fresh its pipeline for what­ev­er the next phase may be.

Fi­bro­Gen will shell out $25 mil­lion in cash for a glob­al li­cense to Boston-area biotech Hi­FiBiO’s galectin-9 plat­form tar­get­ing im­muno-on­col­o­gy and au­toim­mune dis­or­ders, the part­ners said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER